

BMS-564929

Catalog No: tcsc1381



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

627530-84-1

Formula:

$C_{14}H_{12}ClN_3O_3$

Pathway:

Others

Target:

Androgen Receptor

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

305.72

Product Description


BMS-564929 is an **androgen receptor** (AR) agonist, binds to androgen receptor (AR) with a **K_i**

of 2.11 ± 0.16 nM.

IC50 & Target: Ki: 2.11 ± 0.16 nM (Androgen receptor)^[1]

In Vitro: BMS-564929 exhibits a potency (EC_{50} , calculated as the concentration at which 50% of the maximum stimulatory effect of DHT is achieved) of 0.44 ± 0.03 nM in the C2C12 myoblast cell line. In the PEC cell line, the EC_{50} for BMS-564929 is 8.66 ± 0.22 nM. BMS-564929 is more than 1000-fold selective for AR vs. estrogen receptors (ER) α and β , glucocorticoid receptor (GR), and mineralocorticoid receptor (MR), and approximately 400-fold selective vs. progesterone receptor (PR). BMS-564929 shows no measurable activity in functional transactivation assays with ER α/β , GR, MR, or PR at concentrations up to $30 \mu\text{M}$ ^[1].

In Vivo: In sexually mature, castrated male rats, a well-characterized animal model, BMS-564929 (p.o.) shows substantially more potent activity in the levator ani, exhibiting an ED_{50} of 0.0009 mg/kg in the levator ani and an ED_{50} of 0.14 mg/kg in the prostate; a net 160-fold selectivity for muscle vs. prostate. Approximately 100% muscle stimulation is achieved at 0.1 mg/kg, reaching greater than 125% stimulation at 0.3 and 1 mg/kg. Compared with T propionate (TP) in the same model, BMS-564929 is more than 200 times more potent in stimulation of muscle and 80 times more selective for muscle vs. prostate^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!